해부 병리학 시장 규모, 점유율 및 동향 분석 보고서 : 제품 및 서비스별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Anatomic Pathology Market Summary

The global anatomic pathology market size was estimated at USD 38.71 billion in 2025, is projected to grow from USD 41.57 billion in 2026 to reach USD 71.68 billion by 2033, growing at a CAGR of 8.09% from 2026 to 2033. North America dominated the global anatomical pathology market with the largest revenue share of 38.84% in 2025.

The rising global burden of cancer remains one of the most significant growth drivers of the anatomic pathology industry, primarily due to the growing reliance on tissue-based diagnostics for cancer detection, classification, staging, and therapeutic decision-making.

Global Anatomic Pathology Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global anatomic pathology market report based on product & service, application, end use, and region:

• Product & Service Outlook (Revenue, USD Billion, 2021 - 2033)
• Instruments
  • Microtomes & Cryostat
  • Tissue Processors
  • Automatic Stainers
  • Whole Slide Imaging (WSI) Scanners
  • Other Products
• Consumables
  • Reagents & Antibodies
  • Probes & Kits
  • Others
• Services
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• Histopathology
• Cytopathology
• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH)
• Digital Pathology
• Molecular Pathology
• AI-enabled Pathology
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Disease Diagnosis
• Drug Discovery and Development
• Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Research Laboratories
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
  • 1.3.1. Objectives
  • 1.3.2. Objective - 1
  • 1.3.3. Objective - 2
  • 1.3.4. Objective - 3
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product & Application Snapshot
• 2.3. Technology End Use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Global Cancer Burden and Increasing Biopsy Volumes
    • 3.2.1.2. Growing Adoption of Precision Medicine and Biomarker-based Diagnostics
    • 3.2.1.3. Accelerating Adoption of Digital Pathology and AI-enabled Diagnostic Workflows
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Infrastructure and Workflow Modernization Costs Across Pathology Laboratories
    • 3.2.2.2. Stringent Regulatory and Validation Requirements for Advanced Pathology Technologies
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

• 4.1. Anatomic Pathology Market: Product Movement Analysis
  • 4.1.1. Instruments
    • 4.1.1.1. Instruments Market, 2021 - 2033 (USD Billion)
    • 4.1.1.2. Microtomes & Cryostat Microtomes
      • 4.1.1.2.1. Microtomes & Cryostat Microtomes Market, 2021 - 2033 (USD Billion)
    • 4.1.1.3. Tissue Processors
      • 4.1.1.3.1. Tissue Processors Market, 2021 - 2033 (USD Billion)
    • 4.1.1.4. Automatic Strainers
      • 4.1.1.4.1. Automatic Strainers Market, 2021 - 2033 (USD Billion)
    • 4.1.1.5. Whole Sliding Imaging Scanners
      • 4.1.1.5.1. Whole Sliding Imaging Scanners Market, 2021 - 2033 (USD Billion)
    • 4.1.1.6. Other Products
      • 4.1.1.6.1. Other Products Market, 2021 - 2033 (USD Billion)
  • 4.1.2. Consumables
    • 4.1.2.1. Consumables Market, 2021 - 2033 (USD Billion)
    • 4.1.2.2. Antibodies & Reagents
      • 4.1.2.2.1. Antibodies & Reagents Market, 2021 - 2033 (USD Billion)
    • 4.1.2.3. Probes & Kits
      • 4.1.2.3.1. Probes & Kits Market, 2021 - 2033 (USD Billion)
    • 4.1.2.4. Others
      • 4.1.2.4.1. Others Market, 2021 - 2033 (USD Billion)
  • 4.1.3. Services
    • 4.1.3.1. Services Market, 2021 - 2033 (USD Billion)

Chapter 5. Technology Business Analysis

• 5.1. Anatomic Pathology Market: Technology Movement Analysis
  • 5.1.1. Histopathology
    • 5.1.1.1. Histopathology Market, 2021 - 2033 (USD Billion)
  • 5.1.2. Cytopathology
    • 5.1.2.1. Cytopathology Microtomes Market, 2021 - 2033 (USD Billion)
  • 5.1.3. Immunohistochemistry (IHC)
    • 5.1.3.1. Immunohistochemistry (IHC) Market, 2021 - 2033 (USD Billion)
  • 5.1.4. In Situ Hybridization (ISH)
    • 5.1.4.1. In Situ Hybridization (ISH) Market, 2021 - 2033 (USD Billion)
  • 5.1.5. Digital Pathology
    • 5.1.5.1. Digital Pathology Market, 2021 - 2033 (USD Billion)
  • 5.1.6. Molecular Pathology
    • 5.1.6.1. Molecular Pathology Market, 2021 - 2033 (USD Billion)
  • 5.1.7. AI-enabled Pathology
    • 5.1.7.1. AI-enabled Pathology Market, 2021 - 2033 (USD Billion)

Chapter 6. Application Business Analysis

• 6.1. Anatomic Pathology Market: Application Movement Analysis
• 6.2. Disease Diagnosis
  • 6.2.1. Disease Diagnosis Market, 2021 - 2033 (USD Billion)
• 6.3. Drug Discovery & Development
  • 6.3.1. Drug Discovery & Development Market, 2021 - 2033 (USD Billion)
• 6.4. Other
  • 6.4.1. Other Market, 2021 - 2033 (USD Billion)

Chapter 7. End Use Business Analysis

• 7.1. Hospitals
  • 7.1.1. Hospitals Market, 2021 - 2033 (USD Billion)
• 7.2. Diagnostic Laboratories
  • 7.2.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Billion)
• 7.3. Research Laboratories
  • 7.3.1. Research Laboratories Market, 2021 - 2033 (USD Billion)
• 7.4. Others
  • 7.4.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 8. Regional Business Analysis

• 8.1. Anatomical Pathology Market Share By Region, 2025 & 2033
• 8.2. North America
  • 8.2.1. SWOT Analysis
  • 8.2.2. North America Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.2.3. U.S.
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. U.S. Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Target Disease Prevalence
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Mexico Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.2.5. Canada
    • 8.2.5.1. Key Country Dynamics
    • 8.2.5.2. Target Disease Prevalence
    • 8.2.5.3. Competitive Scenario
    • 8.2.5.4. Regulatory Framework
    • 8.2.5.5. Canada Anatomical Pathology Market, 2021 - 2033 (USD Billion)
• 8.3. Europe
  • 8.3.1. SWOT Analysis
  • 8.3.2. Europe Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. UK Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.3.4. Germany
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Germany Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.3.5. Spain
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Spain Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.3.6. France
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. France Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.3.7. Italy
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Italy Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.3.8. Denmark
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Denmark Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.3.9. Sweden
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Sweden Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.3.10. Norway
    • 8.3.10.1. Key Country Dynamics
    • 8.3.10.2. Target Disease Prevalence
    • 8.3.10.3. Competitive Scenario
    • 8.3.10.4. Regulatory Framework
    • 8.3.10.5. Norway Anatomical Pathology Market, 2021 - 2033 (USD Billion)
• 8.4. Asia Pacific
  • 8.4.1. SWOT Analysis
  • 8.4.2. Asia Pacific Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.4.3. Japan
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Japan Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.4.4. China
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. China Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.4.5. India
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. India Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. South Korea Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.4.7. Australia
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Australia Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.4.8. Thailand
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Thailand Anatomical Pathology Market, 2021 - 2033 (USD Billion)
• 8.5. Latin America
  • 8.5.1. SWOT Analysis
  • 8.5.2. Latin America Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.5.3. Brazil
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Brazil Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Argentina Anatomical Pathology Market, 2021 - 2033 (USD Billion)
• 8.6. MEA
  • 8.6.1. SWOT Analysis
  • 8.6.2. MEA Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.6.3. South Africa
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. South Africa Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. UAE Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.6.5. Saudi Arabia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Saudi Arabia Anatomical Pathology Market, 2021 - 2033 (USD Billion)
  • 8.6.6. Kuwait
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. Regulatory Framework
    • 8.6.6.5. Kuwait Anatomical Pathology Market, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Share Analysis, 2022
• 9.4. Company Profiles/Listing
  • 9.4.1. Danaher
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.1.3. Technology Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. PHC Holdings Corporation
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.2.3. Technology Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Quest Diagnostics Incorporated.
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.3.3. Technology Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Laboratory Corporation of America Holdings
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.4.3. Technology Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. F. Hoffmann-La Roche AG
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.5.3. Technology Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Agilent Technologies, Inc.
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.6.3. Technology Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Sakura Finetek USA, Inc.
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.7.3. Technology Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. NeoGenomics Laboratories, Inc.
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.8.3. Technology Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. BioGenex
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.9.3. Technology Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Bio SB
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.10.3. Technology Benchmarking
    • 9.4.10.4. Strategic Initiatives